Global Inflammatory Bowel Disease market is estimated to reach $23.9 billion in 2027, by growing at a CAGR of 4.5% during the forecast period (2021-2027). Increasing public and private investment in healthcare infrastructure is further contributing to the growth of the market. The players in the market are receiving funds for the development of IBD therapies, that is contributing to strengthening the portfolio of the market players, hence, surging the growth of the global IBD market. For instance, BiomX is one of the players that is focused on the development of customized phage therapies that target bacteria in chronic diseases such as IBD. The rise in the number of IBD such as Crohn’s disease and ulcerative colitis is augmenting the growth of the global IBD market. The increasing prevalence of IBD results in the need for research for the prevention of IBD and innovations in healthcare systems to manage this complex and costly disease.
To Request a Sample of our Report on Global Inflammatory Bowel Disease Market: https://www.omrglobal.com/request-sample/ibd-inflammatory-bowel-disease-therapeutics-market
Increasing funding for R&D of new products to promote the growth of the market over the forecast period
Numerous organizations across the globe are working so as to promote the R&D of new treatment alternatives for IBD across the globe. In line with this, in 2018, Crohn’s & Colitis Foundation has received a $3.3 million grant from the Leona M. and Harry B. Helmsley Charitable Trust so as to support the IBD care program initiated by the company. Moreover, in 2018, Patient-Centered Outcomes Research Institute (PCORI) funded $2.4 million to Crohn’s & Colitis Foundation; this was done so as to study the effect of small molecular therapies in IBD.
Scope of the Global Inflammatory Bowel Disease Market
Market Coverage
- Market number available – 2021-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered- By Disease type and Treatment Type
- Regions Covered- North America (US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and Rest of World (Middle East and Africa, Latin America)
- Competitive Landscape- Abbott Laboratories, AbbVie Inc., Allergan, PLC Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc.
Recent Strategic Initiatives in the Global Inflammatory Bowel Disease Market
- In January 2019 Takeda completes acquisition of shire and becoming a global, Value-based, R&D driven biopharmaceutical leader. In January 2019, Takeda announces multiple cell therapy collaborations to advance the company’s novel immuno-oncology portfolio. Further, in December 2018 GARDP, Eisai and Takeda announce a partnership in the search for new antibiotics.
- In May 2018, Allergan PLC launched two IBD clinical research programs for brazikumab, a drug being studied for IBD. Moreover, the company is focussed on focused on R&D in four core areas that are medical aesthetics, eye care, central nervous system, and gastroenterology.
(Get 15% Discount on Buying this Report)
A full Report of Global Inflammatory Bowel Disease Market is Available at: https://www.omrglobal.com/industry-reports/ibd-inflammatory-bowel-disease-therapeutics-market
Global Inflammatory Bowel Disease Market-Segmentation
By Disease Type
- Ulcerative Colitis
- Crohn’s Disease
By Treatment Type
- Surgery
- Anti- Inflammatory Drug Administration
- Steroids
- Immunosuppressant
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
